MedTrace Logo

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

NCT04513028 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-10-30

No results posted yet for this study

Summary

The purpose of this study is to determine how beta-glucan affects the immune system in subjects with melanoma.

Conditions

  • Melanoma Stage III
  • Melanoma Stage IV

Interventions

DIETARY_SUPPLEMENT

Beta-Glucan

500mg (1 capsule) by mouth twice a day for 21 days.

Sponsors & Collaborators

  • Kelly McMasters

    lead OTHER

Principal Investigators

  • Kelly M McMasters, MD · University of Louisville

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-03
Primary Completion
2026-07-31
Completion
2027-01-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04513028 on ClinicalTrials.gov